Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors
Cet article passe en revue les enjeux associés au traitement de la colite à médiation immunitaire chez des patients atteints d'un cancer traité par inhibiteurs de points de contrôle immunitaire
As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstream, their side‐effect profile raises new challenges. In 2011, the Food and Drug Administration approved the first checkpoint inhibitor for the treatment of advanced melanoma, and since then, checkpoint inhibitors have demonstrated efficacy in many other tumor types. Given the frequent use of immune checkpoint inhibitors in a wide range of cancers today, the diagnosis and management of their immune‐mediated toxicities need special attention. One of the most common is immune‐mediated colitis. Workup and management of immune‐mediated colitis can be challenging and is the purpose of this review.